Csl Ltd Stock Price, News & Analysis

CSL Behring AG announced the interim results of its public tender offer for Vifor Pharma Ltd. shares at USD 179.25 each. As of March 2, 2022, CSL holds 74% of Vifor's shares and waived the 80% acceptance condition, declaring the offer successful. An additional acceptance period for the tender offer will start on March 9, 2022, and end on March 22, 2022. Following the offer's completion, CSL plans to seek delisting of Vifor shares from the Swiss Exchange. This acquisition aims to enhance CSL's presence in iron deficiency and nephrology sectors.

CSL Behring AG, a subsidiary of CSL Limited (ASX: CSL; USOTC: CSLLY), has announced a strong acceptance for its public tender offer to acquire Vifor Pharma Ltd. The provisional interim result reveals that CSL holds 74% of Vifor's publicly listed shares as of March 2, 2022. CSL intends to waive the 80% acceptance condition if definitive results are similar or better. The next acceptance period is set for March 9-22, 2022, pending successful completion of the offer. The regulatory approval process remains on track for mid-2022 settlement.

Seqirus has renewed a five-year agreement with the Biomedical Advanced Research and Development Authority (BARDA) to enhance U.S. pandemic preparedness. This partnership, active since 2006, enables BARDA to request influenza vaccines like AUDENZ™ and adjuvants for emergency stockpiling. The agreement focuses on ensuring rapid vaccine production during public health crises. Seqirus's facility in Holly Springs, North Carolina, is equipped to produce up to 150 million doses in an emergency. Additionally, the company continues to innovate in vaccine technology, reinforcing its commitment to public health.

CSL Plasma announced a $125,000 donation to the American Red Cross to support disaster relief across the United States. This funding aims to assist recovery efforts following various disasters, including hurricanes and wildfires. CSL Plasma General Manager Michelle Meyer highlighted the company's commitment to aiding local communities, where their donors and employees reside. The donation will enhance the Red Cross's capacity to respond to disasters effectively, providing essential services like shelter and recovery support.

Seqirus, a unit of CSL Limited (ASX:CSL), announced a $40 million investment in a new 140,000 square foot R&D facility in Waltham, Mass, to enhance its self-amplifying mRNA technology for influenza vaccines. Expected to be operational by mid-2022, the facility will house 300 employees and transition ongoing projects from Cambridge. This investment aligns with Seqirus' goal to improve vaccine effectiveness and reduce dosage requirements. Clinical trials for sa-mRNA vaccines are set to begin this year, furthering CSL's commitment to pandemic preparedness.

CSL Behring released positive long-term results from the Phase 3 HOPE-B trial of etranacogene dezaparvovec (EtranaDez), a gene therapy for hemophilia B. The study showed a stable increase in mean Factor IX (FIX) activity, reaching 36.9 IU/dL at 18 months post-infusion. Participants experienced a 64% reduction in annual bleeding rates and 98% discontinued prophylactic treatment. The therapy was generally well-tolerated, though one unrelated death occurred. This data reinforces the potential of EtranaDez to transform hemophilia B management and may accelerate regulatory reviews in the U.S. and Europe.

CSL Behring AG, a subsidiary of CSL Limited (ASX: CSL; USOTC: CSLLY), has announced its public tender offer for all registered shares of Vifor Pharma Ltd. at an offer price of USD 179.25 per share. The transaction has received unanimous approval from both companies' Boards of Directors. The main offer period is set to begin on February 2, 2022 and end on March 2, 2022. Interested shareholders are advised to review the offer prospectus available on www.CSLtransaction.com.

CSL Behring AG, a subsidiary of CSL Limited (ASX: CSL; USOTC: CSLLY), announced its public tender offer for Vifor Pharma Ltd. at a cash price of USD 179.25 per share. The offer, which aims to enhance CSL’s portfolio in iron deficiency and nephrology, has been approved by both companies’ Boards of Directors. The main offer period is set to start on February 2, 2022, and end on March 2, 2022. Investors are encouraged to review the tender offer documents for complete terms and conditions, available at www.CSLtransaction.com.